Skip to main content
. 2020 Jun 24;18:272–281. doi: 10.1016/j.omto.2020.06.016

Figure 4.

Figure 4

Therapeutic Efficacy of CD28- and 4-1BB-Based CAR-T Cells

(A and B) Response rate and disease progression status of patients after treatment with CD28-based CAR-T cells (A) or 4-1BB-based CAR-T cells (B). (C) Kaplan-Meier curves of relapse-free survival rate after infusion with CD28 CAR-T or 4-1BB CAR-T. (D) Kaplan-Meier curves of overall survival rate after infusion with different CAR-T types. ∗p < 0.05.